Skip to main content

Publications

65 publications

Active

3 grants
  • MPI
    Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.
    NCI · 2025–2030 · via NIH RePORTER
    R01CA296285-02
  • MPI
    Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
    NCI · 2024–2029 · via NIH RePORTER
    R01CA288880-03
  • PI
    Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response
    NCI · 2025–2027 · via NIH RePORTER
    R21CA292178-02
Completed grants (1)
  • PI
    Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK
    NCI · 2018–2024 · via NIH RePORTER
    R01CA233736-06

News mentions

  • Targeting Inflammation May Help Overcome Drug Resistance in Colon Cancer
    May 21, 2026

    According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration.